Topic resource collection
Approved comparison material connected to this topic.
4 resourcesRead both sides
BPC-157 (local injection) VEGF upregulation, angiogenesis promotion 4–8 weeks for pain reduction, 12+ weeks for structural improvement Case series, animal models. No Phase 3 RCTs Most direct mechanism for hypoxic tendon tissue; r…
BPC-157 VEGF upregulation, fibroblast migration Strong. Promotes neovascularization in hypovascular tendon tissue Moderate. Indirect via improved blood supply 250–500 mcg/day Daily subcutaneous Best first-line choice for chronic …
BPC-157 VEGF upregulation, angiogenesis promotion, fibroblast activation 250–500mcg daily subcutaneous VEGFR-2, nitric oxide synthase, collagen synthesis 8–12 weeks for measurable strength improvement First-line choice for chroni…
Mechanism Upregulates VEGF and growth hormone receptors; enhances fibroblast migration to injury site Promotes actin polymerisation and angiogenesis; reduces inflammation via downregulation of pro-inflammatory cytokines Complemen…